Selected research
Industry Research
Coagulation Factor XI Industry Research Report 2026
Market perspective
The global Coagulation Factor XI market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Coagulation Factor XI market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Coagulation Factor XI market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Coagulation Factor XI market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Coagulation Factor XI include Bristol-Myers Squibb Company, Cambryn Biologics LLC, eXithera Pharmaceuticals, Inc, Ionis Pharmaceuticals, Inc., LegoChem Biosciences, Inc and Bayer AG, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Coagulation Factor XI market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Coagulation Factor XI.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Coagulation Factor XI Market by Company
Bristol-Myers Squibb Company
Cambryn Biologics LLC
eXithera Pharmaceuticals, Inc
Ionis Pharmaceuticals, Inc.
LegoChem Biosciences, Inc
Bayer AG
Coagulation Factor XI Segment by Type
MR-1007
IONIS-FXIRx
EP-7041
BMS-262084
AB-022
Others
Coagulation Factor XI Segment by Application
Thrombosis
Acute Ischemic Stroke
Bleeding and Clotting Disorders
Others
Coagulation Factor XI Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Coagulation Factor XI market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Coagulation Factor XI and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Coagulation Factor XI.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Coagulation Factor XI companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- MR-1007
- IONIS-FXIRx
- EP-7041
- BMS-262084
- AB-022
- Others
Applications
- Thrombosis
- Acute Ischemic Stroke
- Bleeding and Clotting Disorders
- Others
Companies covered
- Bristol-Myers Squibb Company
- Cambryn Biologics LLC
- eXithera Pharmaceuticals, Inc
- Ionis Pharmaceuticals, Inc.
- LegoChem Biosciences, Inc
- Bayer AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Coagulation Factor XI by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 MR-1007
- 2.2.3 IONIS-FXIRx
- 2.2.4 EP-7041
- 2.2.5 BMS-262084
- 2.2.6 AB-022
- 2.2.7 Others
- 2.3 Coagulation Factor XI by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Thrombosis
- 2.3.3 Acute Ischemic Stroke
- 2.3.4 Bleeding and Clotting Disorders
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Coagulation Factor XI Breakdown Data by Type
- 3.1 Global Coagulation Factor XI Historic Market Size by Type (2021-2026)
- 3.2 Global Coagulation Factor XI Forecasted Market Size by Type (2027-2032)
4 Coagulation Factor XI Breakdown Data by Application
- 4.1 Global Coagulation Factor XI Historic Market Size by Application (2021-2026)
- 4.2 Global Coagulation Factor XI Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Coagulation Factor XI Market Perspective (2021-2032)
- 5.2 Global Coagulation Factor XI Growth Trends by Region
- 5.2.1 Global Coagulation Factor XI Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Coagulation Factor XI Historic Market Size by Region (2021-2026)
- 5.2.3 Coagulation Factor XI Forecasted Market Size by Region (2027-2032)
- 5.3 Coagulation Factor XI Market Dynamics
- 5.3.1 Coagulation Factor XI Industry Trends
- 5.3.2 Coagulation Factor XI Market Drivers
- 5.3.3 Coagulation Factor XI Market Challenges
- 5.3.4 Coagulation Factor XI Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Coagulation Factor XI Players by Revenue
- 6.1.1 Global Top Coagulation Factor XI Players by Revenue (2021-2026)
- 6.1.2 Global Coagulation Factor XI Revenue Market Share by Players (2021-2026)
- 6.2 Global Coagulation Factor XI Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Coagulation Factor XI Head Office and Area Served
- 6.4 Global Coagulation Factor XI Players, Product Type & Application
- 6.5 Global Coagulation Factor XI Manufacturers Established Date
- 6.6 Global Coagulation Factor XI Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Coagulation Factor XI Market Size (2021-2032)
- 7.2 North America Coagulation Factor XI Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Coagulation Factor XI Market Size by Country (2021-2026)
- 7.4 North America Coagulation Factor XI Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Coagulation Factor XI Market Size (2021-2032)
- 8.2 Europe Coagulation Factor XI Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Coagulation Factor XI Market Size by Country (2021-2026)
- 8.4 Europe Coagulation Factor XI Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Coagulation Factor XI Market Size (2021-2032)
- 9.2 Asia-Pacific Coagulation Factor XI Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Coagulation Factor XI Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Coagulation Factor XI Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Coagulation Factor XI Market Size (2021-2032)
- 10.2 South America Coagulation Factor XI Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Coagulation Factor XI Market Size by Country (2021-2026)
- 10.4 South America Coagulation Factor XI Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Coagulation Factor XI Market Size (2021-2032)
- 11.2 Middle East & Africa Coagulation Factor XI Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Coagulation Factor XI Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Coagulation Factor XI Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Bristol-Myers Squibb Company
- 12.1.1 Bristol-Myers Squibb Company Company Information
- 12.1.2 Bristol-Myers Squibb Company Business Overview
- 12.1.3 Bristol-Myers Squibb Company Revenue in Coagulation Factor XI Business (2021-2026)
- 12.1.4 Bristol-Myers Squibb Company Coagulation Factor XI Product Portfolio
- 12.1.5 Bristol-Myers Squibb Company Recent Developments
- 12.2 Cambryn Biologics LLC
- 12.2.1 Cambryn Biologics LLC Company Information
- 12.2.2 Cambryn Biologics LLC Business Overview
- 12.2.3 Cambryn Biologics LLC Revenue in Coagulation Factor XI Business (2021-2026)
- 12.2.4 Cambryn Biologics LLC Coagulation Factor XI Product Portfolio
- 12.2.5 Cambryn Biologics LLC Recent Developments
- 12.3 eXithera Pharmaceuticals, Inc
- 12.3.1 eXithera Pharmaceuticals, Inc Company Information
- 12.3.2 eXithera Pharmaceuticals, Inc Business Overview
- 12.3.3 eXithera Pharmaceuticals, Inc Revenue in Coagulation Factor XI Business (2021-2026)
- 12.3.4 eXithera Pharmaceuticals, Inc Coagulation Factor XI Product Portfolio
- 12.3.5 eXithera Pharmaceuticals, Inc Recent Developments
- 12.4 Ionis Pharmaceuticals, Inc.
- 12.4.1 Ionis Pharmaceuticals, Inc. Company Information
- 12.4.2 Ionis Pharmaceuticals, Inc. Business Overview
- 12.4.3 Ionis Pharmaceuticals, Inc. Revenue in Coagulation Factor XI Business (2021-2026)
- 12.4.4 Ionis Pharmaceuticals, Inc. Coagulation Factor XI Product Portfolio
- 12.4.5 Ionis Pharmaceuticals, Inc. Recent Developments
- 12.5 LegoChem Biosciences, Inc
- 12.5.1 LegoChem Biosciences, Inc Company Information
- 12.5.2 LegoChem Biosciences, Inc Business Overview
- 12.5.3 LegoChem Biosciences, Inc Revenue in Coagulation Factor XI Business (2021-2026)
- 12.5.4 LegoChem Biosciences, Inc Coagulation Factor XI Product Portfolio
- 12.5.5 LegoChem Biosciences, Inc Recent Developments
- 12.6 Bayer AG
- 12.6.1 Bayer AG Company Information
- 12.6.2 Bayer AG Business Overview
- 12.6.3 Bayer AG Revenue in Coagulation Factor XI Business (2021-2026)
- 12.6.4 Bayer AG Coagulation Factor XI Product Portfolio
- 12.6.5 Bayer AG Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst